OTC Markets OTCPK · Stocky rates: Cautious

MEDIPAL HOLDINGS CORP (MEPDF)

$18.35 ▲ +0.00% as of 24 Aug, 09:48

Stocky turns companies like MEDIPAL HOLDINGS CORP into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.

Try Stocky free →
53
/ 100
Neutral

What Stocky thinks

Cautious. MEPDF scores below-average on growth (36.5) and value (44) metrics, with mixed leadership alignment (59) that suggests moderate founder/insider conviction. The Vulnerability Index of 100 reflects structural risks or market headwinds that have not been fully assessed; this opacity warrants caution until clearer visibility emerges on competitive positioning and earnings durability.

Compounder Score
44/100
Business quality — profitability, growth, capital efficiency.
Leadership Alignment
59/100
Founder-led, insider ownership, capital allocation history.
Vulnerability
100/100
Downside resilience — customer concentration, supply chain, refinancing risk.
Value Score
44/100
Valuation vs peers and history — is this a good price to pay?

What Stocky gives investors that other tools don't

Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for MEDIPAL HOLDINGS CORP:

53
VERDICT

Stocky Verdict — one score, everything

Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 53/100, you know instantly whether to dig deeper or skip.

Rated
MOAT

Moat Score — is there a real edge?

Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.

59
LEADER

Leadership Alignment — is management on your side?

Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.

100
RISK

Vulnerability Profile — what could break?

Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.

Elite
TRACK

Track Record — does the system work?

Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.

24/7
ALERTS

Alerts + Portfolio insights

Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.

MEDIPAL HOLDINGS CORP (MEPDF) — frequently asked

Is MEDIPAL HOLDINGS CORP (MEPDF) a good investment right now?

Stocky rates MEDIPAL HOLDINGS CORP (MEPDF) at 53/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. MEPDF scores below-average on growth (36.5) and value (44) metrics, with mixed leadership alignment (59) that suggests moderate founder/insider conviction. The Vulnerability Index of 100 reflects structural risks or market headwin

What is MEPDF's Stocky Verdict?

MEPDF's current Stocky Verdict is 53/100, placing it in the "Cautious" band. This composite combines a 44/100 Compounder score, 59/100 Leadership, Moat rating, and analyst signal.

Does MEDIPAL HOLDINGS CORP have a competitive moat?

Stocky hasn't finalised a Moat Score for MEDIPAL HOLDINGS CORP yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.

Is MEDIPAL HOLDINGS CORP's leadership aligned with shareholders?

MEDIPAL HOLDINGS CORP scores 59/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.

What are the biggest risks to MEPDF?

MEDIPAL HOLDINGS CORP's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to MEDIPAL HOLDINGS CORP.

This is just the surface. See the whole picture on MEDIPAL HOLDINGS CORP.

Sign up free and unlock the full analysis on MEPDF — the same tools professional analysts use, personalised to your portfolio:

  • Every analyst covering MEPDF — full list with star ratings, price targets, historical hit-rate. Not just the top 3 you see above.
  • Full Vulnerability Profile — customer concentration, refinancing walls, stress-test scenarios (-20% revenue, +200bp rates) modelled specifically for MEPDF.
  • Bull & bear thesis — the AI-written counter-argument every retail investor forgets to read.
  • Portfolio fit check — how MEPDF changes your sector concentration, correlation and Verdict-weighted quality.
  • Ask Stocky AI — "What are the biggest 3-year risks to MEPDF?" · "Is MEPDF overvalued vs its 5-year median?" · unlimited follow-ups on your portfolio.
  • Live alerts — analyst target changes, insider buys, big moves — the day they happen.
Start free · 14 days Plus, no card →

Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.

STOCKY VERDICT
53
/ 100 · Neutral

See MEDIPAL HOLDINGS CORP the Stocky way

This page is just a preview. Open the live, interactive version for the full picture:

Stocky Verdict
A plain-English Buy / Hold / Sell score out of 100.
Compounder & Value scores
How strong the business is — and whether it looks cheap.
Interactive charts
1M to 5Y price history with company events plotted on it.
Top analyst targets
What the best-rated Wall Street analysts expect next.
What if? simulator
See what an investment in MEPDF would be worth today.
Practice portfolio
Buy MEPDF with virtual money and track it — zero risk.
Free · no real money · learn by doing Open MEPDF in Stocky →

Or jump straight to the interactive dashboard for MEPDF in the app.